ZTS
ZOETIS INC.
$77.74
장중 · Vol 364.1K · 52주 $71.00–$155.38 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $76.38 · Aug 31, 2026
ZTS 가격 추세
종가
$76.38
시가
$77.00
고가
$76.56
저가
$75.63
30초 브리핑
ZTS 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 8%
연중 저점권입니다. 반등 신호보다 하락 원인을 먼저 확인하세요.
Forward P/E 11.8배
선행 P/E가 낮아 시장은 이익 증가를 반영하고 있습니다.
20일 평균의 1.0배
거래량은 최근 평균 범위입니다.
2026-11-03
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
ZTS 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
10 Sylvan Way · Parsippany, NJ, United States · 직원 14,500명
시가총액
$31.86B
Trailing P/E
12.6
최근 12개월 이익 기준
Forward P/E
11.8
이익 증가 기대 반영
EPS (TTM)
$6.11
배당 수익률
2.74%
배당성향
33.6%
베타
0.73
시장보다 방어적
ROE
64.9%
P/B
9.84
EV/EBITDA
9.7
52주 범위
$71.00 – $155.38
현재 위치 8%
거래량
5.05M
20일 평균 4.85M · 1.0배
애널리스트 의견
매수 50%
총 18명 · 0m
DITM LEAPS Analysis
ZTS 장기 DITM 콜옵션을 진입 적합도 순으로 비교
| Contract | Expiry | Strike | Price | Lev. | Delta | Extrinsic | Spread | IV | OI | Score | 상세 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ZTS280121C00045000 | 1/21/28 · 1.4Y | $45.00 | $35.05 | 1.9x | 0.8824 | 9.5% | 12.27% | 61.18% | 107 | 79.16 | |
| ZTS280121C00050000 | 1/21/28 · 1.4Y | $50.00 | $31.60 | 2.1x | 0.8559 | 15.4% | 10.76% | 57.64% | 926 | 76.96 | |
| ZTS270917C00050000 | 9/17/27 · 1.0Y | $50.00 | $29.60 | 2.3x | 0.8680 | 9.7% | 11.49% | 55.96% | 6 | 75.85 | |
| ZTS280121C00055000 | 1/21/28 · 1.4Y | $55.00 | $27.90 | 2.3x | 0.8233 | 22.1% | 15.05% | 56.20% | 111 | 67.57 | |
| ZTS280121C00060000 | 1/21/28 · 1.4Y | $60.00 | $24.65 | 2.5x | 0.7931 | 32.1% | 7.71% | 50.18% | 673 | 65.11 | |
| ZTS270917C00060000 | 9/17/27 · 1.0Y | $60.00 | $22.65 | 2.7x | 0.7910 | 26.2% | 16.34% | 53.32% | 2 | 58.74 | |
| ZTS280121C00065000 | 1/21/28 · 1.4Y | $65.00 | $22.00 | 2.6x | 0.7521 | 46.7% | 10.00% | 50.51% | 91 | 51.81 |
재무제표
ZTS 연간 손익·현금흐름·재무상태
매출 성장률
+2.3%
최근 연간 YoY
EPS 성장률
+10.1%
최근 연간 YoY
영업이익률
38.0%
최근 연간
FCF 마진
24.1%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $9.47B+2.3% | $9.26B+8.3% | $8.54B+5.7% | $8.08B |
| 매출총이익 | $6.80B+4.0% | $6.54B+9.3% | $5.98B+6.3% | $5.63B |
| 영업이익 | $3.60B+6.0% | $3.39B+10.5% | $3.07B+4.8% | $2.93B |
| 순이익 | $2.67B+7.5% | $2.49B+6.1% | $2.34B+10.9% | $2.11B |
| 희석 EPS | $6.02+10.1% | $5.47+7.9% | $5.07+12.9% | $4.49 |
| EBITDA | $4.07B+5.6% | $3.85B+5.2% | $3.67B+9.7% | $3.34B |
| 영업현금흐름 | $2.90B-1.7% | $2.95B+25.5% | $2.35B+23.1% | $1.91B |
| 잉여현금흐름 | $2.28B-0.7% | $2.30B+41.8% | $1.62B+22.2% | $1.33B |
| 총자산 | $15.47B+8.6% | $14.24B-0.3% | $14.29B-4.3% | $14.93B |
| 총부채 | $9.24B+37.0% | $6.74B-0.2% | $6.75B-16.5% | $8.09B |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
ZTS 실적·배당 일정
매출 하단
$2.24B
EPS 하단
$1.44
매출 상단
$2.35B
배당 지급일
2026-09-01
오늘
실적 발표일
2026-11-03
D-63
EPS 상단
$1.60
매출 컨센서스
$2.29B
EPS 컨센서스
$1.51
배당락일
2026-07-20
43일 전
최근 배당
| 배당락일 | 주당 배당 |
|---|---|
| Jul 20, 2026 | $0.5300 |
| Apr 20, 2026 | $0.5300 |
| Jan 20, 2026 | $0.5300 |
| Oct 31, 2025 | $0.5000 |
| Jul 18, 2025 | $0.5000 |
| Apr 21, 2025 | $0.5000 |
| Jan 21, 2025 | $0.5000 |
| Oct 31, 2024 | $0.4320 |
뉴스
ZTS 관련 최신 기사
제품·기술Michael Burry Bought Beaten-Down Stocks And Shorted AI Favorites — Here’s How His August Bets Fared
The AI rally put Burry’s bearish stance under pressure as Palantir, CoreWeave, Oracle, Micron, Tesla, Nebius and Nvidia all climbed during August.
Stocktwits · Aug 31, 2026
실적Phibro Animal Health Q4 Earnings Call Highlights
Phibro Animal Health (NASDAQ:PAHC) reported record fiscal 2026 sales and a sharp increase in adjusted EBITDA, supported by growth in its Animal Health and Mineral Nutrition businesses, the integration of its acquired Zoetis medicated feed additive portfolio, and operational initiatives under its Phi
MarketBeat · Aug 27, 2026
실적Phibro Animal Health Corporation Q4 2026 Earnings Call Summary
Moby summary of Phibro Animal Health Corporation's Q4 2026 earnings call
Moby · Aug 27, 2026
실적Zoetis Wins Emergency Authorization for Simparica Trio, Can It Support a Slowing U.S. Business?
The timing of Zoetis Inc.’s (NYSE:ZTS) latest regulatory win is particularly relevant for shareholders. Just one week after the animal-health company reported a 7% decline in U.S. revenue and an 11% drop in domestic companion-animal product sales, Simparica Trio received Emergency Use Authorization to treat New World screwworm infestations in dogs and puppies. The treatment […]
Insider Monkey · Aug 24, 2026
- 실적
Zoetis Earnings Reveal a Divided Business, But Can its Pipeline Restore Growth?
Zoetis Inc. (NYSE:ZTS) entered 2026 as a leader in animal health, but its latest earnings show that even a strong market position cannot fully insulate the company from weaker consumer demand. Fiscal Q2 2026 revenue remained flat at $2.5 billion and declined 1% on an organic operational basis, as pressure in the U.S. companion-animal market […]
Insider Monkey · Aug 23, 2026
M&A3 of Wall Street’s Favorite Stocks We’re Skeptical Of
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
StockStory · Aug 21, 2026
실적Zoetis (ZTS) Stock Still Looks Cheap After a 62% Slide
Zoetis stock has had a tough run over the last few years, yet the current valuation checks suggest the shares may now be pricing in a lot of that bad news. After a prolonged slide, the question is whether the current market price properly reflects Zoetis' earnings power and risks. Over the past 5 years, Zoetis shareholders have seen the share price decline about 61.8%, which points to a significant reset in expectations. Recent investor focus is on how competition and softer pet care...
Simply Wall St. · Aug 19, 2026
- 실적
Is Zoetis’ Lowered 2026 Outlook and Simparica Trio EUA Altering The Investment Case For Zoetis (ZTS)?
Zoetis recently received an Emergency Use Authorization from the U.S. FDA for its Simparica Trio chewable to treat life-threatening New World screwworm infestations in dogs and puppies, while also appointing experienced healthcare executive Jay Saccaro as its new Chief Financial Officer and Chief Operating Officer. At the same time, Zoetis lowered its full-year 2026 revenue and earnings guidance, signaling a more cautious outlook even as it expands the clinical reach of one of its flagship...
Simply Wall St. · Aug 19, 2026
제품·기술Should You Continue to Retain PAHC Stock in Your Portfolio?
Phibro Animal Health's Animal Health growth and global reach support its outlook, but Brazil's antimicrobial transition and trade risks cloud near-term prospects.
Zacks · Aug 19, 2026
주주환원3 High-Yielding Dividend Stocks That Have Doubled Their Payouts in 5 Years
These stocks have been generous with their dividend increases, and more may be on the way.
Motley Fool · Aug 19, 2026
홀더
ZTS 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
100.2%
기관 보유 (유동주식)
100.4%
내부자 보유
0.2%
기관 수
2,065
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| Blackrock Inc. | 39.43M | $3.04B | 9.5% | 10.8% | Jun 30, 2026 |
| Vanguard Capital Management LLC | 26.03M | $2.01B | 6.3% | -0.2% | Jun 30, 2026 |
| Vanguard Portfolio Management LLC | 23.86M | $1.84B | 5.8% | -0.4% | Jun 30, 2026 |
| State Street Corporation | 19.67M | $1.52B | 4.8% | 1.8% | Jun 30, 2026 |
| State Farm Mutual Automobile Insurance Co | 15.89M | $1.23B | 3.9% | 0.0% | Jun 30, 2026 |
| Geode Capital Management, LLC | 13.29M | $1.02B | 3.2% | 17.1% | Jun 30, 2026 |
| Wellington Management Group, LLP | 9.42M | $726.58M | 2.3% | -7.1% | Jun 30, 2026 |
| Morgan Stanley | 8.88M | $684.56M | 2.1% | -37.2% | Jun 30, 2026 |
| Nordea Investment Management AB | 6.59M | $508.29M | 1.6% | 12.4% | Jun 30, 2026 |
| Deutsche Bank AG | 5.85M | $451.17M | 1.4% | 5.8% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.